ZANVASTRO
- Product NDC
- 71860-304
- Requested package NDC
- 71860-304-01
- 11-digit product format
- 718600304
- Labeler code
- 71860
- Product ID
- 71860-304_5b752db5-061f-8804-e063-6394a90aa4af
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- zilganersen
- Dosage form
- KIT
- Labeler
- Ionis Pharmaceuticals Inc.
- Application
- NDA220210
- Marketing category
- NDA
- Marketing start
- 2026-09-03
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N220210-001 | ZANVASTRO | ZILGANERSEN SODIUM | EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) | SOLUTION / INTRATHECAL | RLD, RS | 2026-09-03 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N220210-001 | 11786546 | 2041-05-20 | U-4601 | Drug substance, Drug product | 2026-09-22 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N220210-001 | ZANVASTRO | EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) | SOLUTION / INTRATHECAL | RLD, RS | 2026-09-03 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N220210-001 | ZANVASTRO | EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) | SOLUTION / INTRATHECAL | RLD, RS | 2026-09-03 | c2088c7a36db… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N220210-001 | 11786546 | 2041-05-20 | U-4601 | Drug substance, Drug product | 2026-09-22 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | N220210-001 | 11786546 | 2041-05-20 | U-4601 | Drug substance, Drug product | 2026-09-22 | c2088c7a36db… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- ZANVASTRO
- Listing expiration
- 2027-12-31
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| af6ca330-46d3-4ed6-b2af-bd6db3133fd1 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ZANVASTRO | ZILGANERSEN | Ionis Pharmaceuticals Inc. | af6ca330-46d3-4ed6-b2af-bd6db3133fd1 | 2026-09-14 | Warnings, Adverse reactions | 220210 NDA220210 71860-304-01 71860-304 71860030401 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 71860-304-01 | 71860030401 | 1 KIT in 1 CARTON (71860-304-01) * 21 mL in 1 VIAL, SINGLE-DOSE (71860-200-01) * 2.8 mL in 1 VIAL, SINGLE-DOSE (71860-104-01) | 1 kit | 2026-09-03 | No | No | Current |